ERRATUM| May 27, 2025

John TD, Walters MC, Rangarajan HG, et al. Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease. Blood Adv. 2024;8(23):6055-6063.

Blood Adv (2025) 9 (10): 2460.

https://doi.org/10.1182/bloodadvances.2025016356

Page 6059: due to a production error, the numbering and the alignment of the lettered items in Table 3 are incorrect. In the online version, the numbering and lettering in this table are incorrect. The corrected Table 3 is shown below.

© 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

2025

Table 3.

Adjudication survey.

Pain
Number of severe pain events and/or hospitalizations for acute VOP events per year for the last 2 years? ______ Prescribed hydroxyurea therapy? Yes ___ No ___ Baseline labs prior to starting hydroxyurea: Hemoglobin Hemoglobin F MCV Platelets If yes, current hydroxyurea dose and for how long at this dose: _____ Hemoglobin Hemoglobin F MCV Platelets Does the treating hematologist believe the patient has been adherent to their hydroxyurea therapy? What is the local definition of maximum tolerated dose of hydroxyurea (MTD HU)? Did the patient meet the local definition of MTD HU? Yes ____ No____ Specify any side effects: ________ Prescribed other therapies to decrease VOEs? L-glutamine: Yes ___ No____ If yes, when started: ______ Maximum dose used: _____ Any side effects at MTD? Yes ____ No_____ If yes, provide details: _____ Crizanlizumab: Yes____ No____ If yes, when started: ____ Maximum dose used: ____ Any side effects of MTD? Yes___ No___ If yes, provide details: ____ Chronic blood transfusions: Yes___ No___ If yes, when started, length of time on transfusions: _____ Has the possibility of pain associated with the following been evaluated? Menstrual cycle: Yes ___ No___ NA___ Traumatic event or stress (e.g., divorce, trauma, domestic violence) as precipitating pain been discussed with the: Patient alone? Yes___ No___ Parent alone? Yes___ No___ AVN or spinal compression fracture? Yes___ No___ Not evaluated___ If yes to any of the above, have they been addressed or still on-going? ______ History of asthma? Yes___ No___ Did the first episode of ACS occur before 4 years of age? Yes___ No___ Evidence of optimal asthma medical care (e.g., controller medication that matches asthma severity) _______ Referral to an asthma specialist? Yes___ No___ Has the treating hematologist attending provided a statement that the patient has been prescribed disease modifying therapy for sickle cell disease, asthma, or both, and despite evidence of adherence continues to have acute VOEs? Yes___ No___
Priapism (Only report episodes happening at least 4 hours)
Number of priapism events per week/month for the last 12 months managed at home? _____ Number of hospitalizations for priapism events per year for last 2 years? ____ Length of each priapism episode documented in the medical record?

Pain
Number of severe pain events and/or hospitalizations for acute VOP events per year for the last 2 years? ______ Prescribed hydroxyurea therapy? Yes ___ No ___ Baseline labs prior to starting hydroxyurea: Hemoglobin Hemoglobin F MCV Platelets If yes, current hydroxyurea dose and for how long at this dose: _____ Hemoglobin Hemoglobin F MCV Platelets Does the treating hematologist believe the patient has been adherent to their hydroxyurea therapy? What is the local definition of maximum tolerated dose of hydroxyurea (MTD HU)? Did the patient meet the local definition of MTD HU? Yes ____ No____ Specify any side effects: ________ Prescribed other therapies to decrease VOEs? L-glutamine: Yes ___ No____ If yes, when started: ______ Maximum dose used: _____ Any side effects at MTD? Yes ____ No_____ If yes, provide details: _____ Crizanlizumab: Yes____ No____ If yes, when started: ____ Maximum dose used: ____ Any side effects of MTD? Yes___ No___ If yes, provide details: ____ Chronic blood transfusions: Yes___ No___ If yes, when started, length of time on transfusions: _____ Has the possibility of pain associated with the following been evaluated? Menstrual cycle: Yes ___ No___ NA___ Traumatic event or stress (e.g., divorce, trauma, domestic violence) as precipitating pain been discussed with the: Patient alone? Yes___ No___ Parent alone? Yes___ No___ AVN or spinal compression fracture? Yes___ No___ Not evaluated___ If yes to any of the above, have they been addressed or still on-going? ______ History of asthma? Yes___ No___ Did the first episode of ACS occur before 4 years of age? Yes___ No___ Evidence of optimal asthma medical care (e.g., controller medication that matches asthma severity) _______ Referral to an asthma specialist? Yes___ No___ Has the treating hematologist attending provided a statement that the patient has been prescribed disease modifying therapy for sickle cell disease, asthma, or both, and despite evidence of adherence continues to have acute VOEs? Yes___ No___
Priapism (Only report episodes happening at least 4 hours)
Number of priapism events per week/month for the last 12 months managed at home? _____ Number of hospitalizations for priapism events per year for last 2 years? ____ Length of each priapism episode documented in the medical record?

The survey was completed by enrolling institutions and reviewed by the adjudication committee.

AVN, avascular necrosis; MCV, mean corpuscular volume; NA, not applicable; VOE, vaso occlusive event.

John TD, Walters MC, Rangarajan HG, et al. Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease. Blood Adv. 2024;8(23):6055-6063.

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

John TD, Walters MC, Rangarajan HG, et al. Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease. Blood Adv. 2024;8(23):6055-6063. Open Access

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

John TD, Walters MC, Rangarajan HG, et al. Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease. Blood Adv. 2024;8(23):6055-6063.